Australia markets closed

Inovio Pharmaceuticals, Inc. (0A43.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
10.59+0.57 (+5.66%)
At close: 07:02PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.12
52-week change 3868.67%
S&P500 52-week change 321.08%
52-week high 312.71
52-week low 30.33
50-day moving average 35.53
200-day moving average 31.72

Share statistics

Avg vol (3-month) 328.86k
Avg vol (10-day) 315.8k
Shares outstanding 5N/A
Implied shares outstanding 6N/A
Float 823.03M
% held by insiders 11.48%
% held by institutions 116.63%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 20.083333:1
Last split date 325 Jan 2024

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-26,686.29%

Management effectiveness

Return on assets (ttm)-32.11%
Return on equity (ttm)-79.55%

Income statement

Revenue (ttm)832.01k
Revenue per share (ttm)0.04
Quarterly revenue growth (yoy)-17.70%
Gross profit (ttm)N/A
EBITDA -130.66M
Net income avi to common (ttm)-135.12M
Diluted EPS (ttm)-1.54
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)145.29M
Total cash per share (mrq)6.22
Total debt (mrq)30.21M
Total debt/equity (mrq)25.74%
Current ratio (mrq)3.60
Book value per share (mrq)5.15

Cash flow statement

Operating cash flow (ttm)-124.37M
Levered free cash flow (ttm)-86.15M